Orbimed Advisors LLC
About Orbimed Advisors LLC’s 13F portfolio
Orbimed Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Orbimed Advisors LLC reported $5.3B across 121 US-listed positions (). Its largest position is EDGEWISE THERAPEUTICS INC (EWTX) at 12% of the reported book, and its ten biggest holdings make up 43% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | $41.37 −1.59% | 12% | 15.5M | $630.5M |
| 2 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | $44.89 −4.18% | 6.5% | 6.8M | $343.9M |
| 3 | NYSE: LLY ELI LILLY & CO | $1,382.75 −2.32% | 5.9% | 258K | $309.3M |
| 4 | NASDAQ: MBX MBX BIOSCIENCES INC | $53.42 +0.60% | 3.6% | 3.4M | $189.3M |
| 5 | NASDAQ: SVA SINOVAC BIOTECH LTD | $6.47 0.00% | 3.5% | 2.7M | $184.5M |
| 6 | NASDAQ: AZN ASTRAZENECA PLC | $178.76 −1.93% | 3.2% | 916K | $171.1M |
| 7 | NASDAQ: GPCR STRUCTURE THERAPEUTICS INC | $17.36 −4.46% | 2.2% | 2.2M | $118.6M |
| 8 | NASDAQ: SION SIONNA THERAPEUTICS INC | $2.97 −3.26% | 2.1% | 2.6M | $112.4M |
| 9 | NASDAQ: CRVS CORVUS PHARMACEUTICALS INC | $10.19 +0.20% | 2.0% | 7.2M | $107.0M |
| 10 | NASDAQ: AVBP ARRIVENT BIOPHARMA INC | $10.90 +1.96% | 2.0% | 3.0M | $105.2M |
| 11 | NASDAQ: GH GUARDANT HEALTH INC | $145.14 +1.30% | 1.7% | 584K | $87.6M |
| 12 | NASDAQ: ARGX ARGENX SE | $941.25 −0.66% | 1.6% | 93K | $86.2M |
| 13 | NYSE: MRK MERCK & CO INC | $137.78 −3.90% | 1.6% | 663K | $85.2M |
| 14 | NASDAQ: QURE UNIQURE NV | $20.30 −2.31% | 1.6% | 1.8M | $83.3M |
| 15 | NASDAQ: PRAX PRAXIS PRECISION MEDICINES I | $305.19 +0.04% | 1.5% | 230K | $77.0M |
| 16 | NYSE: EW EDWARDS LIFESCIENCES CORP | $105.23 −0.19% | 1.4% | 835K | $75.5M |
| 17 | NASDAQ: PRLD PRELUDE THERAPEUTICS INC | $3.30 −0.60% | 1.4% | 13.7M | $73.2M |
| 18 | NASDAQ: ABVX ABIVAX SA | $83.83 +2.11% | 1.4% | 547K | $72.8M |
| 19 | NASDAQ: DYN DYNE THERAPEUTICS INC | $15.87 −0.94% | 1.4% | 3.2M | $71.9M |
| 20 | NASDAQ: NTRA NATERA INC | $289.50 +0.71% | 1.3% | 262K | $71.1M |
| 21 | NASDAQ: CGON CG ONCOLOGY INC | $80.00 +1.34% | 1.3% | 973K | $69.1M |
| 22 | NYSE: UNH UNITEDHEALTH GROUP INC | $349.91 −10.21% | 1.3% | 161K | $67.0M |
| 23 | NASDAQ: SPRY ARS PHARMACEUTICALS INC | $3.69 +1.10% | 1.3% | 8.3M | $66.4M |
| 24 | NASDAQ: ASND ASCENDIS PHARMA A/S | $270.33 −0.32% | 1.2% | 244K | $65.2M |
| 25 | NYSE: HUM HUMANA INC | $385.78 −12.98% | 1.2% | 164K | $65.2M |
Showing 1–25 of 121 positions on this page reported in this 13F.
- Healthcare97%
- Industrials0.6%
- AddedLLYELI LILLY & CO+8.9%$309.3M
- AddedAZNASTRAZENECA PLC+36.6%$171.1M
- AddedGPCRSTRUCTURE THERAPEUTICS INC+49.7%$118.6M
- AddedGHGUARDANT HEALTH INC+34.1%$87.6M
- AddedPRAXPRAXIS PRECISION MEDICINES I+33.4%$77.0M
- AddedPRLDPRELUDE THERAPEUTICS INC+25.8%$73.2M
- AddedABVXABIVAX SA+17.4%$72.8M
- AddedDYNDYNE THERAPEUTICS INC+10.9%$71.9M
- AddedCGONCG ONCOLOGY INC+2.6%$69.1M
- NewUNHUNITEDHEALTH GROUP INC—$67.0M
- ReducedELVNENLIVEN THERAPEUTICS INC−14.9%$343.9M
- ReducedMBXMBX BIOSCIENCES INC−5.7%$189.3M
- ReducedSIONSIONNA THERAPEUTICS INC−27.6%$112.4M
- ReducedARGXARGENX SE−32.2%$86.2M
- ReducedQUREUNIQURE NV−15.4%$83.3M
- ReducedEWEDWARDS LIFESCIENCES CORP−32.2%$75.5M
- ReducedBSXBOSTON SCIENTIFIC CORP−37.7%$63.3M
- ReducedISRGINTUITIVE SURGICAL INC−24.3%$62.8M
- ReducedXENEXENON PHARMACEUTICALS INC−15.8%$53.9M
- ReducedSYKSTRYKER CORPORATION−12.8%$50.1M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | PRLD Prelude Therapeutics Inc | 13D | 16.0% | 12.9M | Filed 23 APR 2026 |
| 2 | QTTB Q32 Bio Inc. | 13D | 15.4% · 2 classes | 2.3M | Filed 12 MAR 2026 |
| 3 | EWTX Edgewise Therapeutics, Inc. | 13D | 14.5% | 15.3M | Filed 12 MAY 2025 |
| 4 | ADRX ADARx Pharmaceuticals, Inc. | 13D | 14.0% | 14.9M | Filed 02 OCT 2026 |
| 5 | BRVE Braveheart Bio, Inc. | 13D | 13.5% | 12.2M | Filed 10 SEP 2026 |
| 6 | ASPE Aspen Neuroscience, Inc. | 13D | 12.3% | 3.6M | Filed 06 NOV 2026 |
| 7 | TRAW Traws Pharma, Inc. | 13D | 11.9% | 1.9M | Filed 05 MAY 2026 |
| 8 | ETRA Electra Therapeutics, Inc. | 13D | 11.0% | 6.9M | Filed 25 SEP 2026 |
| 9 | CRVS CORVUS PHARMACEUTICALS, INC. | 13D | 10.3% | 8.6M | Filed 27 JAN 2026 |
| 10 | STTK Shattuck Labs, Inc. | 13D | 10.0% · 2 classes | 9.0M | Filed 15 JUN 2026 |
| 11 | XLO Xilio Therapeutics, Inc. | 13G | 10.0% | 642K | Filed 15 MAY 2026 |
| 12 | VYNE Yarrow Bioscience, Inc. | 13D | 10.0% | 266K | Filed 05 AUG 2026 |
| 13 | ACET Adicet Bio, Inc. | 13D | 9.6% · 2 classes | 14.8M | Filed 10 OCT 2025 |
| 14 | ELVN Enliven Therapeutics, Inc. | 13D | 9.5% · 2 classes | 6.8M | Filed 24 JUN 2026 |
| 15 | CMPX Compass Therapeutics, Inc. | 13D | 8.9% | 15.2M | Filed 15 AUG 2025 |
| 16 | WHWK Whitehawk Therapeutics, Inc. | 13G | 8.9% · 2 classes | 4.2M | Filed 15 MAY 2025 |
| 17 | BLSM BlossomHill Therapeutics, Inc. | 13D | 8.9% | 2.7M | Filed 18 AUG 2026 |
| 18 | SION Sionna Therapeutics, Inc. | 13D | 8.4% · 2 classes | 3.7M | Filed 13 FEB 2025 |
| 19 | NPCE NeuroPace Inc | 13G | 8.0% | 2.6M | Filed 14 AUG 2025 |
| 20 | FBRX Forte Biosciences, Inc. | 13G | 8.0% | 510K | Filed 14 FEB 2025 |
| 21 | MBX MBX Biosciences, Inc. | 13D | 7.7% · 2 classes | 3.6M | Filed 11 FEB 2026 |
| 22 | AVBP ArriVent BioPharma, Inc. | 13D | 7.5% · 2 classes | 3.0M | Filed 13 AUG 2025 |
| 23 | NSPR InspireMD, Inc. | 13G | 7.4% | 3.1M | Filed 17 FEB 2026 |
| 24 | SCTX Scribe Therapeutics, Inc. | 13D | 7.2% | 1.3M | Filed 29 JUL 2026 |
| 25 | IMA ImageneBio, Inc. | 13D | 6.9% · 2 classes | 774K | Filed 30 JUL 2025 |
Showing 1–25 of 29 disclosed stakes. 10 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Orbimed Advisors LLC’s 13F portfolio
Orbimed Advisors LLC’s $5.3B 13F book is spread across 121 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 43%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are EWTX, ELVN, LLY, MBX and SVA, led by EDGEWISE THERAPEUTICS INC (EWTX) at 12% of the portfolio. The heaviest sector exposure is Healthcare (97%), then Industrials (1%).
What Orbimed Advisors LLC changed last quarter
Between 2026-03-31 and Q2 2026, Orbimed Advisors LLC was a net buyer: it opened 35 new positions and added to 32 more, while trimming 26 and closing 21 outright. Against a 121-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ELI LILLY & CO (LLY), and its biggest reduction was ENLIVEN THERAPEUTICS INC (ELVN).
What a 13F does and doesn’t reveal
A 13F captures only Orbimed Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Orbimed Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Orbimed Advisors LLC's profile on this page is built directly from those filings.
How current is the 13F data on Orbimed Advisors LLC's page?
It reflects Orbimed Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Orbimed Advisors LLC files its next quarterly report, this page refreshes automatically.
Can I see Orbimed Advisors LLC's complete list of holdings?
This page highlights Orbimed Advisors LLC's largest positions rather than all 121 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Orbimed Advisors LLC's filings.
Does a 13F show everything Orbimed Advisors LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Orbimed Advisors LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Orbimed Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

